News

Monday August 23, 2021

Notice of Interim Results and Investor Presentation

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Interim Results and Investor Presentation Brighton, United Kingdom – 23rd August 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage […]

Monday August 2, 2021

Secondary endpoint analysis from Phase 2b trial

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Update on secondary endpoint analysis from recent positive Phase 2b trial Cardiac surgery patients receiving XF-73 nasal gel exhibited a valuable, sustained […]